SRRK — Scholar Rock Holding Corporation stock price, charts and financials

QT44Scholar Rock Holding Corporation

Scholar Rock Holding Corporation (NASDAQ: SRRK) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
46.65
-2.37-4.83%
OverviewShort InterestFilings
SRRKQT44Scholar Rock Holding Corporation·NASDAQ
46.65-4.83%
News
Down 4.8% — Scholar Rock Holding Corporation $SRRK Shares Bought by Engineers Gate Manager LP (defenseworld.net).
Medium confidence
TA
Loading chart...
Signal & projected range
Gap down — mean-reversionHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
LGND-0.42%$283.49ORKA-2.83%$94.96MIRM-7.07%$91.83TVTX-3.06%$62.76PTCT-3.87%$65.37CRSP-1.34%$56.56DNTH-4.26%$96.81COGT-5.09%$31.50
Snapshot
Index-P/E-EPS (ttm)-3.08Insider Own47.83%Shs Outstand119.83MPerf Week-15.81%
Market Cap5.68BForward P/E-EPS next Y-2.61Insider Trans-0.14%Shs Float96.39MPerf Month-17.45%
Enterprise Value5.29BPEG-EPS next Q-0.87Inst Own-Short Float18.68%Perf Quarter-1.44%
Income-113.00MP/S118.94EPS this Y-7.81%Inst Trans-Short Ratio13.67Perf Half Y2.53%
Sales47.00MP/B22.01EPS next Y21.39%ROA-78.04%Short Interest18.01MPerf YTD5.90%
Book/sh2.12P/C11.36EPS next 5Y-ROE-160.19%52W High61.76 -24.47%Perf Year46.01%
Cash/sh4.11P/FCF-EPS past 3/5Y-ROIC-88.80%52W Low27.07 72.33%Perf 3Y666.01%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility6.38% 4.70%Perf 5Y23.84%
Dividend TTM-EV/Sales112.66EPS Y/Y TTM-24.70%Oper. Margin0.00%ATR (14)2.72Perf 10Y-
Dividend Ex-Date-Quick Ratio7.02Sales Y/Y TTM-Profit Margin0.00%RSI (14)30.72Recom2.00
Dividend Gr. 3/5Y-Current Ratio7.02EPS Q/Q14.29%SMA20-15.19%Beta0.61Target Price70.40
Payout0.00%Debt/Eq0.45Sales Q/Q-SMA50-11.77%Rel Volume2.14Prev Close49.02
Employees289LT Debt/Eq0.42EarningsNov 13SMA200-3.27%Avg Volume1.52MPrice46.65
IPO DateMay 25, 2018Option/ShortYes / YesEPS/Sales Surpr.0.06% -Net Debt/EBITDA0.59Volume3,252,777Change-4.83%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-15-26ReiteratedHC Wainwright & Co.Buy$65 → $70
Sep-15-26DowngradeBarclaysOverweight → Equal Weight$58
Sep-15-26ReiteratedWedbushOutperform$64 → $70
Sep-15-26ReiteratedEvercore ISI GroupOutperform$72
Sep-15-26ReiteratedPiper SandlerOverweight$58 → $75
Sep-14-26ReiteratedRaymond JamesStrong Buy$53 → $72
Sep-14-26ReiteratedTruist SecuritiesBuy$55 → $76
Sep-14-26ReiteratedBMO CapitalOutperform$76 → $84
Sep-14-26ReiteratedWedbushOutperform$64 → $70
Aug-21-26ReiteratedWedbushOutperform$58 → $64
Latest News· Times ET
Sep-17-26
Sep-17-2611:13PM
Scholar Rock Holding Corporation $SRRK Shares Bought by Engineers Gate Manager LPdefenseworld.net
Sep-15-26
Sep-15-2607:16PM
Scholar Rock (SRRK) Stock Fair Value Edges Higher After Isembyld Approval And Analyst RevisionsYahoo
11:11AM
Scholar Rock: Reiterating 'Strong Buy' On FDA Approval SMA And Expansions Now In Playseekingalpha.com
04:04AM
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Autodesk, Eli Lilly, Etsy, Lear, Netskope, Nokia, Northrop Grumman, Rapid7, Rivian Automotive, Ulta Beauty, and More247wallst.com
Sep-14-26
Sep-14-2611:01AM
Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcriptseekingalpha.com
05:24AM
Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophybenzinga.com
04:38AM
Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vialreuters.com
01:50AM
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarketbenzinga.com
Sep-11-26
Sep-11-2602:25PM
Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)businesswire.com
01:27PM
US FDA approves Scholar Rock's muscle weakness drugreuters.com
Sep-10-26
Sep-10-2608:57AM
Scholar Rock Holding Corporation (SRRK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcriptseekingalpha.com
Sep-08-26
Sep-08-2602:39AM
HC Wainwright & Co. Reiterates Buy on Scholar Rock Holding, Maintains $65 Price TargetBenzinga
Sep-07-26
Sep-07-2606:23AM
Scholar Rock: Manufacturing Noise Obscures A Muscle-Targeted Franchiseseekingalpha.com
Sep-02-26
Sep-02-2604:03AM
Scholar Rock Receives FDA's Fast Track And Orphan Drug Designations For Apitegromab To Treat Facioscapulohumeral Muscular DystrophyBenzinga
04:00AM
Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trialbusinesswire.com
Company

Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue
4700——————
Cost of Goods Sold Incl. D&A1152082——————
Gross Profit-68-208-2——————
Selling, General and Administrative Excl. Other4117668——————
Research and Development115208183——————
Other Operating Expense-115-208-1——————
Operating Income-109-385-252——————
Interest Expense177——————
Unusual Expense
—————————
Non-Operating Income (Expense)-11413——————
Net Income Before Taxes-113-378-246——————
Income Taxes
000——————
Consolidated Net Income-113-378-246——————
Net Income From Continuing Operations-113-378-246——————
Net Income-113-378-246——————
EPS (Recurring)-3.12-3.29-2.47——————
EPS (Basic, Before Extraordinaries)-3.12-3.29-2.47——————
EPS (Diluted)-3.08-3.29-2.47——————
EBITDA-108-369-238——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio
36.72————————
Gross Margin
-144.68————————
Operating Margin
-231.91————————
Net Margin
-240.43————————
Shares Outstanding37115100——————
Market Capitalization1,7265,0664,322——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$64.86$54.42$43.98$33.54$23.10● Close Price0.00M5.00M9.99M14.99M19.99MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
FLIER JEFFREY S.DirectorJul 01 '26Sale53.883,053164,49027,856Jul 06
Gilman MichaelDirectorJul 01 '26Sale53.882,544137,05859,511Jul 06
Burow KristinaDirectorJul 01 '26Sale53.743,053164,064114,657Jul 06
Reed JoshuaDirectorJul 01 '26Sale53.743,053164,06819,518Jul 06
Peng KatieDirectorJul 01 '26Sale53.885,446293,40534,301Jul 06
Burow KristinaDirectorApr 23 '26Option Exercise9.1389,800820,324110,871Apr 24
Woods KeithChief Operating OfficerApr 16 '26Sale49.5710,220506,651620,055Apr 20
Vaishnaw AkshayPresident of R&DApr 16 '26Sale49.5712,246607,089630,542Apr 20
Sinha VikasChief Financial OfficerApr 16 '26Sale49.5710,410516,071619,856Apr 20
Hallal DavidChief Executive OfficerApr 16 '26Sale49.5730,6151,517,7231,639,034Apr 20
Qatanani MoCHIEF SCIENTIFIC OFFICERFeb 23 '26Sale47.078,484399,35198,445Feb 25
Marantz Jing L.CHIEF MEDICAL OFFICERFeb 17 '26Sale46.534,157193,418126,012Feb 19
Ho JunlinGENERAL COUNSELFeb 17 '26Sale46.539,580445,740241,545Feb 19
Parlavecchio CarynCHROFeb 17 '26Sale46.539,035420,382169,087Feb 19
Qatanani MoCHIEF SCIENTIFIC OFFICERFeb 17 '26Sale46.537,989371,714106,929Feb 19
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.